{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:24:12Z","timestamp":1780514652856,"version":"3.54.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008069","name":"University of California, San Francisco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019748","name":"Johns Hopkins University Press","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jcpo.2025.100588","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T11:45:20Z","timestamp":1746099920000},"page":"100588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Minimal residual disease negative: A novel endpoint for accelerated approval; What providers should know"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0684-4263","authenticated-orcid":false,"given":"Sruthi","family":"Ranganathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6110-8221","authenticated-orcid":false,"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcpo.2025.100588_bib1","unstructured":"Facts About Measurable Residual Disease (MRD). \u3008https:\/\/www.lls.org\/sites\/default\/files\/2021-05\/FSHP5_MRD_Factsheet_Apil2021.pdf\u3009."},{"issue":"20","key":"10.1016\/j.jcpo.2025.100588_bib2","article-title":"New criteria for response assessment: role of minimal residual disease in multiple myeloma","volume":"125","author":"B","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcpo.2025.100588_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/2643-3230.BCD-24-0292","article-title":"Minimal residual disease as an early endpoint for accelerated drug approval in myeloma: a roadmap","volume":"6","author":"Landgren","year":"2025","journal-title":"Blood Cancer Discov."},{"issue":"4","key":"10.1016\/j.jcpo.2025.100588_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.jcpo.2025.100588_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/GO.22.00119","article-title":"Global myeloma trial participation and drug access in the era of novel therapies","author":"Fatoki","year":"2022","journal-title":"JCO Glob. Oncol."},{"issue":"1","key":"10.1016\/j.jcpo.2025.100588_bib6","article-title":"Utility of tumor-informed circulating tumor DNA for detection of minimal residual disease after curative-intent therapy in localized pancreatic cancer","volume":"2","author":"Dickey","year":"2025","journal-title":"Surg. Oncol. Insight"},{"key":"10.1016\/j.jcpo.2025.100588_bib7","doi-asserted-by":"crossref","unstructured":"Minimal Residual Disease Testing in Relapsed Systemic AL Amyloidosis | Blood | American Society of Hematology. \u3008https:\/\/ashpublications.org\/blood\/article\/144\/Supplement%201\/3302\/532961\/Minimal-Residual-Disease-Testing-in-Relapsed\u3009, (Accessed 22 April 2025).","DOI":"10.1182\/blood-2024-200434"},{"issue":"10","key":"10.1016\/j.jcpo.2025.100588_bib8","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.jcpo.2025.100588_bib9","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.jcpo.2025.100588_bib10","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.jcpo.2025.100588_bib11","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10218","key":"10.1016\/j.jcpo.2025.100588_bib12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jcpo.2025.100588_bib13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.jcpo.2025.100588_bib14","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.jcpo.2025.100588_bib15","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.jcpo.2025.100588_bib16","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism following BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.jcpo.2025.100588_bib17","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Ak","year":"2024","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jcpo.2025.100588_bib18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/2643-3230.BCD-23-0176","article-title":"An embarrassment of riches: three FDA-approved bispecific antibodies for relapsed refractory multiple myeloma","volume":"4","author":"Firestone","year":"2023","journal-title":"Blood Cancer Discov."},{"issue":"5","key":"10.1016\/j.jcpo.2025.100588_bib19","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bjh.18568","article-title":"Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: a surrogacy analysis","volume":"200","author":"Etekal","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jcpo.2025.100588_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1231720","article-title":"Multiple myeloma: challenges with deciding the optimal sequencing strategy","volume":"14","author":"Walia","year":"2023","journal-title":"Front. Pharm."},{"issue":"11","key":"10.1016\/j.jcpo.2025.100588_bib21","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.jcpo.2025.100588_bib22","article-title":"Novel endpoints based on tumor size ratio to support early clinical decision-making in oncology drug-development","volume":"52","author":"S","year":"2024","journal-title":"J. Pharmacokinet. Pharmacodyn."}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538325000323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538325000323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T08:22:39Z","timestamp":1772180559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538325000323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":22,"alternative-id":["S2213538325000323"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2025.100588","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimal residual disease negative: A novel endpoint for accelerated approval; What providers should know","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2025.100588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100588"}}